<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574388</url>
  </required_header>
  <id_info>
    <org_study_id>2018P000854</org_study_id>
    <nct_id>NCT04574388</nct_id>
  </id_info>
  <brief_title>Evaluation of Open-Label Conditioned Placebo Analgesia for Postoperative Opioid Reduction Following Spinal Fusion</brief_title>
  <acronym>COLP</acronym>
  <official_title>Evaluation of Open-Label Conditioned Placebo Analgesia for Postoperative Opioid Reduction Following Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to understand the impact of conditioned open label placebo (COLP) on&#xD;
      opioid consumption and pain after surgery. The hypothesis being tested is that by pairing a&#xD;
      non-deceptive placebo pill with regularly prescribed pain killers after surgery, will allow&#xD;
      reduction in opioids taken while maintaining the same level of analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be enrolled at preoperative clinic.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. aged 18-75 years&#xD;
&#xD;
        2. scheduled for spinal fusion surgery&#xD;
&#xD;
        3. able to comprehend and willingness to participate in COLP&#xD;
&#xD;
        4. willingness to undergo psychophysical and psychosocial testing&#xD;
&#xD;
        5. willingness to participate in long-term follow-up.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. delirium, psychosis, or other cognitive impairment limiting completion of study&#xD;
           procedures&#xD;
&#xD;
        2. non-English speaking&#xD;
&#xD;
        3. contraindication to opioid usage&#xD;
&#xD;
      Preoperative psychosocial and pain questionnaires will be completed using a secure email link&#xD;
      to REDcap, and brief quantitative sensory testing performed.&#xD;
&#xD;
      After completion of preoperative testing, they will be randomized to one of 2 treatments:&#xD;
      COLP or treatment as usual (TAU).&#xD;
&#xD;
      Day of surgery: Patient will undergo scheduled spinal fusion and admitted for post-operative&#xD;
      recovery as per normal surgical management. No restrictions on intraoperative anesthetics or&#xD;
      post-operative pain management options will be made. Intraoperative medication use, including&#xD;
      opioids, as well as post-operative opioid consumption and pain scores will be extracted from&#xD;
      the medical record.&#xD;
&#xD;
      Inpatient and outpatient postoperative period: The study investigator or research assistant&#xD;
      (RA) will train the participant and nursing staff in the self-administration of COLP with&#xD;
      each analgesic administration in hospital, beginning on POD 0, pairing one open label placebo&#xD;
      pill with each analgesic medication administration. Beginning on POD 2, patients will&#xD;
      additionally be instructed to take a scheduled placebo pill at least 3 times/day, and in&#xD;
      conjunction with their ongoing instances of PRN opioid utilization. Opioid administration and&#xD;
      pain scores will be recorded in a daily diary, which the RA will help fill out on POD1 and 2&#xD;
      with them. At hospital discharge, the patients' bottle of placebo pills will be replenished.&#xD;
      Patients will be instructed to continue scheduled and PRN use of opioids, and encouraged to&#xD;
      use placebo pills. After discharge, the number of placebo and opioid pills that they use, as&#xD;
      well as average pain at rest and with movement each day will be collected for up to 21 days&#xD;
      via email linking to Redcap system. If preferred, patients will answer questions through&#xD;
      daily SMS TEXT or telephone call, using a secure study phone. To protect patient's privacy&#xD;
      there will be no identifiable information in the text messages. The SMS texts will be sent&#xD;
      from a dedicated study phone that is MobileIron enabled. MobileIron is software used by&#xD;
      Partners HealthCare that allows for more secure data management.&#xD;
&#xD;
      Follow-up visit: At surgical follow-up visit, patients will repeat baseline testing and&#xD;
      participants in the COLP group will undergo a 15-minute semi-structured interview to&#xD;
      determine the patient's experience with managing post-operative pain with COLP. Long term&#xD;
      follow-up on pain, psychosocial impact and opioid use will be accomplished using the Redcap&#xD;
      email survey system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>self administration of PRN opioids</measure>
    <time_frame>day 3-17</time_frame>
    <description>daily report of post-discharge opioid use in sub-acute postoperative period, converted into morphine milligram equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute postoperative pain</measure>
    <time_frame>day 3-17</time_frame>
    <description>daily brief pain inventory (BPI)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Spine Surgery</condition>
  <arm_group>
    <arm_group_label>open label placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants will take open label placebo pills TID and in conjunction with other PRN analgesics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment as usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>participants will take PRN analgesics as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>open label placebo</intervention_name>
    <description>open label placebo pill</description>
    <arm_group_label>open label placebo</arm_group_label>
    <other_name>non-deceptive placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) aged 18-75 years, (2) scheduled for spinal fusion surgery up to, and including 4&#xD;
             levels, (3) able to comprehend and willingness to participate in COLP, (4) willingness&#xD;
             to undergo psychophysical and psychosocial testing (5) willingness to participate in&#xD;
             long-term follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) delirium, psychosis, or other cognitive impairment limiting completion of study&#xD;
             procedures (2) non-English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Schreiber, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Kristin Schreiber</investigator_full_name>
    <investigator_title>Assistant Professor, Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>open label placebo</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

